Drug Approval | May 06, 2024
Briefs: Eugia Pharma Specialities and IOL Chemicals and Pharmaceuticals
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
The company has posted net profit of Rs.30.35 crores for the Financial Year ended March 31, 2024
Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics, USA
The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Subscribe To Our Newsletter & Stay Updated
